Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B

NCT03938792

Last updated date
Study Location
Klinikum der Johann Wolfgang Goethe-Universität, Medizinische Klinik II,
Frankfurt am Main, , 60590, Germany
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hemophilia A, Hemophilia B
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
12-74 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Participants with a diagnosis of severe hemophilia A or B with a minimum weight of 30 kg at screening.

- Participant or legally authorized representative, or participant's caregiver capable of giving signed informed consent (or minor assent, when applicable).

Participants who are enrolled into the Non-Inhibitor Cohort must also meet the following criteria:

- No detectable or documented history of inhibitors

- Participants on FVIII/FIX routine prophylaxis who have demonstrated at least 80% compliance with scheduled prophylaxis regimen during 6 months prior to enrollment and are willing to continue to receive routine prophylaxis treatment with FVIII/FIX replacement during the Observational Phase.

- Participants with on-demand treatment regimen with ≥6 acute bleeding episodes (spontaneous or traumatic) that required coagulation factor infusion during the 6 months period prior to enrollment and willing to continue to receive on demand treatment during the Observational Phase.

Participants who are enrolled into the Inhibitor Cohort must also meet the following criteria:

- Documentation of current high titer inhibitor (≥5 BU/mL) or current low titer inhibitor (<5 BU/mL) refractory to FVIII or FIX replacement and with FVIII or FIX recovery <60% of expected within previous 6 months prior to enrolment into the Observational Phase

- Participants with on-demand treatment regimen with ≥6 bleeding episodes (spontaneous and/or traumatic) necessitating treatment with bypass factor during the 6 months prior to enrollment in the Observation Phase and willing to continue to receive on-demand treatment during this phase.

- Participants who have documented inhibitors while on factor-replacement therapy but who do not meet the quantitative inhibitor criteria described in the prior bullet at the time of Screening (eg, participant with a previously documented high-titer inhibitor (≥5 BU/mL) and whose condition precludes re-challenge with FVIII or FIX replacement) may be considered for eligibility on a case-by-case basis with prior approval from the Pfizer Medical Monitor

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Previous or current treatment for and/or history of coronary artery diseases, venous
or arterial thrombosis or ischemic disease


- Known planned surgical procedure during the planned study period.


- Known hemostatic defect other than hemophilia A or B.


- Abnormal renal or hepatic function


- Current unstable liver or biliary disease


- Abnormal hematologic parameters


- Other acute or chronic medical or psychiatric condition or laboratory abnormality that
may increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator,


- Current routine prophylaxis with bypassing agent or non-coagulation non-factor-
replacement therapy


- Regular, concomitant therapy with immunomodulatory drugs


- Ongoing or planned use of immune tolerance induction or prophylaxis with FVIII or FIX
replacement during the Active Treatment Phase.


- Previous exposure to PF 06741086 during to participation in studies B7841002 and
B7841003.


- Participation in other studies involving investigational drug(s) within 30 days (or as
determined by local requirements) or 5 half-lives prior to study entry and/or during
study participation.


- CD4 cell count ≤200/uL if human immunodeficiency virus (HIV)-positive


- Screening ECG that demonstrates clinically relevant abnormalities that may affect
participant safety or interpretation of study results.


- Individuals with hypersensitivity or an allergic reaction to hamster protein or other
components of the study intervention.


- Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
participants who are Pfizer employees, including their family members, directly
involved in the conduct of the study.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hemophilia A, Hemophilia BStudy of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B
NCT03938792
  1. Frankfurt am Main,
  2. Muscat,
  3. Istanbul,
  4. Little Rock, Arkansas
  5. Tampa, Florida
  6. New Hyde Park, New York
  7. Pleven,
  8. Sofia,
  9. Hong Kong,
  10. Hong Kong,
  11. Surat, Gujarat
  12. Pune, Maharashtra
  13. Pune, Maharashtra
  14. Nagoya, Aichi
  15. Kashihara, Nara
  16. Fuchu, Tokyo
  17. Setagaya-ku, Tokyo
  18. Hiroshima,
  19. Daegu,
  20. Seoul,
  21. Seoul,
  22. Samara,
  23. Belgrade,
  24. Belgrade,
  25. Kragujevac,
  26. Nis,
  27. Novi Sad,
  28. Palma de Mallorca, Islas Baleares
  29. Kaohsiung,
  30. Adana,
  31. Ankara,
  32. Ankara,
  33. Antalya,
  34. Gaziantep,
  35. Istanbul,
  36. Izmir,
  37. Izmir,
  38. Kayseri,
  39. Samsun,
  40. Trabzon,
Male
12 Years+
years
MULTIPLE SITES
Hemophilia A, Hemophilia BUnderstanding Hemophilia A and B Drug Dosage Administration Patterns
NCT03248141
  1. Gainesville, Florida
  2. Las Vegas, Nevada
  3. Fort Worth, Texas
ALL GENDERS
0+
years
MULTIPLE SITES
Hemophilia A, Hemophilia BStudy Evaluating Approach to Treatment of Haemophilia A and B in Spain
NCT00581438
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B
Official Title  ICMJE An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A or B Patients With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis
Brief Summary Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors. The potential for once weekly (QW) subcutaneous (SC) administration provides for treatment options in the absence of reliable vascular access, increased convenience and may enable better compliance. Combined, these qualities should result in a reduction of bleeding episodes.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Intervention Model: Crossover Assignment
Intervention Model Description:
This is a one way Cross-Over Prevention study with 1 Arm that has No masking.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Hemophilia A
  • Hemophilia B
Intervention  ICMJE Drug: PF-06741086
300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
Study Arms  ICMJE Experimental: PF-06741086
Participants will be assigned to treatment with PF-06741086 after a 6 month Observation Phase on their current hemophilia regimen.
Intervention: Drug: PF-06741086
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 2, 2019)
145
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE August 12, 2023
Estimated Primary Completion Date August 12, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria

  • Participants with a diagnosis of severe hemophilia A or B with a minimum weight of 30 kg at screening.
  • Participant or legally authorized representative, or participant's caregiver capable of giving signed informed consent (or minor assent, when applicable).

Participants who are enrolled into the Non-Inhibitor Cohort must also meet the following criteria:

  • No detectable or documented history of inhibitors
  • Participants on FVIII/FIX routine prophylaxis who have demonstrated at least 80% compliance with scheduled prophylaxis regimen during 6 months prior to enrollment and are willing to continue to receive routine prophylaxis treatment with FVIII/FIX replacement during the Observational Phase.
  • Participants with on-demand treatment regimen with ?6 acute bleeding episodes (spontaneous or traumatic) that required coagulation factor infusion during the 6 months period prior to enrollment and willing to continue to receive on demand treatment during the Observational Phase.

Participants who are enrolled into the Inhibitor Cohort must also meet the following criteria:

  • Documentation of current high titer inhibitor (?5 BU/mL) or current low titer inhibitor (<5 BU/mL) refractory to FVIII or FIX replacement and with FVIII or FIX recovery <60% of expected within previous 6 months prior to enrolment into the Observational Phase
  • Participants with on-demand treatment regimen with ?6 bleeding episodes (spontaneous and/or traumatic) necessitating treatment with bypass factor during the 6 months prior to enrollment in the Observation Phase and willing to continue to receive on-demand treatment during this phase.
  • Participants who have documented inhibitors while on factor-replacement therapy but who do not meet the quantitative inhibitor criteria described in the prior bullet at the time of Screening (eg, participant with a previously documented high-titer inhibitor (?5 BU/mL) and whose condition precludes re-challenge with FVIII or FIX replacement) may be considered for eligibility on a case-by-case basis with prior approval from the Pfizer Medical Monitor

Exclusion Criteria

  • Previous or current treatment for and/or history of coronary artery diseases, venous or arterial thrombosis or ischemic disease
  • Known planned surgical procedure during the planned study period.
  • Known hemostatic defect other than hemophilia A or B.
  • Abnormal renal or hepatic function
  • Current unstable liver or biliary disease
  • Abnormal hematologic parameters
  • Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator,
  • Current routine prophylaxis with bypassing agent or non-coagulation non-factor- replacement therapy
  • Regular, concomitant therapy with immunomodulatory drugs
  • Ongoing or planned use of immune tolerance induction or prophylaxis with FVIII or FIX replacement during the Active Treatment Phase.
  • Previous exposure to PF 06741086 during to participation in studies B7841002 and B7841003.
  • Participation in other studies involving investigational drug(s) within 30 days (or as determined by local requirements) or 5 half-lives prior to study entry and/or during study participation.
  • CD4 cell count ?200/uL if human immunodeficiency virus (HIV)-positive
  • Screening ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
  • Individuals with hypersensitivity or an allergic reaction to hamster protein or other components of the study intervention.
  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are Pfizer employees, including their family members, directly involved in the conduct of the study.
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Gender Based Eligibility:Yes
Ages  ICMJE 12 Years to 74 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Bulgaria,   Germany,   Hong Kong,   India,   Japan,   Korea, Republic of,   Oman,   Russian Federation,   Serbia,   Spain,   Taiwan,   Turkey,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03938792
Other Study ID Numbers  ICMJE B7841005
2018-003660-31 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP